Evidence map›Paper›PMID 40503613›Full record

ArticleThe Journal of infectious diseases2025

Priming or Boosting Plasmodium falciparum Transmission-Blocking Responses With Recombinant Vaccines or Gametocyte Extract.

Yiting Song, Bingbing Deng, Carole A Long, Qinzhe Li, Mahamadou Diakite, Wei-Chiao Huang, Shiqi Zhou, Yuan Luo, Danton Ivanochko, Randall S MacGill and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yiting SongDepartment of Biomedical Engineering, State University of New York at Buffalo, Buffalo, New York, USA.ORCID 0009-0001-6429-4293
Bingbing DengLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.
Carole A LongLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.
Qinzhe LiDepartment of Biomedical Engineering, State University of New York at Buffalo, Buffalo, New York, USA.
Mahamadou DiakiteMalaria Research and Training Center, Faculty of Medicine, Pharmacy, and Odontostomatology, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.ORCID 0000-0002-4268-8857
Wei-Chiao HuangDepartment of Biomedical Engineering, State University of New York at Buffalo, Buffalo, New York, USA.
Shiqi ZhouDepartment of Biomedical Engineering, State University of New York at Buffalo, Buffalo, New York, USA.
Yuan LuoDepartment of Biomedical Engineering, State University of New York at Buffalo, Buffalo, New York, USA.
Danton IvanochkoProgram in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, Ontario, Canada.
Randall S MacGillCenter for Vaccine Innovation and Access, PATH, Washington, District of Columbia, USA.
Jean-Philippe JulienProgram in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, Ontario, Canada.ORCID 0000-0001-7602-3995
Kazutoyo MiuraLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.ORCID 0000-0003-4455-2432
Jonathan F LovellDepartment of Biomedical Engineering, State University of New York at Buffalo, Buffalo, New York, USA.ORCID 0000-0002-9052-884X

Funding

Rationally-Designed, Spontaneous-Particleized Pfs48/45 for a Multivalent Malaria VaccineR01AI148557 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI JULIEN, JEAN-PHILIPPE, LOVELL, JONATHAN F · 2020 to 2024
$2.1M
NIAID NIH HHS R01 AI148557
6 · The paper itself

Abstract

Plasmodium falciparum infection can induce antibody responses to the parasitic, gametocyte-expressed antigens Pfs48/45 and Pfs230. Retrospective analysis of healthy individuals from malaria-endemic Mali showed increasing prevalence of antibodies to these antigens from infancy to age 17 years, an expected response to malaria exposure. This supports examining the immune interplay between gametocyte exposure and vaccination with these antigens as transmission-blocking vaccine (TBV) candidates. Recombinant Pfs48/45 and Pfs230 were formulated with a liposome-display vaccine adjuvant system. In mice primed with either antigen, subsequent gametocyte extract (GE) exposure significantly boosted antibody responses. Dose-dependent GE exposure induced transmission-reducing activity (TRA) in Pfs48/45-primed mice but not in naive controls. Conversely, GE-primed mice exhibited enhanced TRA after Pfs48/45 vaccination. These findings demonstrate bidirectional immune priming and highlight the potential for TBVs to elicit stronger TRA responses upon subsequent natural malaria exposure and/or in endemic areas in individuals with preexisting antibodies to TBV antigens.

Indexed as

Antigens, ProtozoanMalaria, FalciparumMalaria VaccinesPlasmodium falciparumAdolescentAdultAnimalsAntibodies, ProtozoanChildChild, PreschoolFemaleHumansImmunization, SecondaryInfantMaleMaliAntibodies, ProtozoanAntigens, ProtozoanMalaria VaccinesMembrane GlycoproteinsPfs230 antigen, Plasmodium falciparumpfs48-45 protein, Plasmodium falciparumProtozoan ProteinsVaccines, SyntheticgametocyteliposomemalariaPfs48transmission-blocking vaccine

Identifiers

PMID40503613
PMCPMC13381284

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.